Methods of treating heart failure and fibrotic disorders using modified relaxin polypeptides
US11311605B2 · kind B2 · utility
0Cited by
194References
24Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 27, 2020 |
| Grant date | Apr 26, 2022 |
| Priority date | — |
| Expiry date | May 27, 2040 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K38/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Modified relaxin polypeptides and their uses thereof are provided. Exemplary embodiments provide relaxin polypeptides which include one or more amino acid substitutions with natural or non-naturally encoded amino acids, and/or linkage to a water-soluble polymer, such as polyethylene glycol. Additionally, use of said relaxin polypeptides for treatment of disease, such as heart failure, is also provided.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.